Form 4: Baker Bros. Boosts Madrigal Pharma Stake

Baker Bros. Advisors and affiliated entities significantly increased their indirect beneficial ownership in Madrigal Pharmaceuticals, Inc. through multiple common stock purchases in August 2025.

Summary

• Baker Bros. Advisors LP and its affiliated entities, including 667, L.P. and Baker Brothers Life Sciences, L.P., acquired a total of 100,165 shares of Madrigal Pharmaceuticals, Inc. common stock.
• The purchases occurred on August 18, 2025, and August 20, 2025.
• Transaction prices ranged from a weighted average of $372.8693 to $392.2429 per share.
• Following these transactions, the reporting persons' indirect beneficial ownership totals 2,150,781 shares of common stock.
• Julian C. Baker and Dr. Raymond Cheong, directors of Madrigal Pharmaceuticals, Inc., are associated with the reporting entities, with other reporting persons deemed directors by deputization.

Sentiment

Score: 8

Explanation: The substantial insider buying by a major institutional investor and affiliated directors signals strong confidence in the company's future, which is a highly positive indicator for the stock.

Positives

• Significant insider buying by a major institutional investor (Baker Bros. Advisors LP) and affiliated funds, signaling strong confidence in Madrigal Pharmaceuticals' future prospects.
• The purchases were made at varying price points, indicating a strategic accumulation of shares.
• The increased stake by a 10% owner and director-affiliated entities suggests alignment of interests with long-term shareholder value.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding Madrigal Pharmaceuticals' future operations or financial performance. It solely reports changes in beneficial ownership.

Management Comments

• Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP, are directors of Madrigal Pharmaceuticals, Inc.
• By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Julian C. Baker are deemed directors by deputization of the Issuer.
• The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the 'Staff'), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Industry Context

This insider buying activity by a prominent biotech investor group like Baker Bros. Advisors in Madrigal Pharmaceuticals, a company focused on liver diseases, suggests a positive outlook on the company's pipeline or market position within the competitive pharmaceutical and biotechnology sector. Such investments can be seen as a vote of confidence in the company's long-term value proposition, especially given the high-risk, high-reward nature of drug development.

Comparison to Industry Standards

• Insider buying by significant shareholders and directors, especially by specialized biotech funds like Baker Bros., is generally viewed positively by the market as it signals strong conviction in the company's prospects, often outperforming general market sentiment.
• Compared to typical institutional portfolio adjustments, the substantial increase in stake by Baker Bros. in Madrigal Pharmaceuticals is notable, indicating a strategic long-term position rather than short-term trading.
• While specific comparable companies or projects are not mentioned, Baker Bros. has a history of significant investments in other successful biotech firms, making their increased stake in MDGL a potentially strong indicator for the company's future.

Related Party Transactions

• Julian C. Baker and Dr. Raymond Cheong, directors of Madrigal Pharmaceuticals, Inc., are associated with the reporting entities (Baker Bros. Advisors LP and its affiliates) that conducted the stock purchases.
• The Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) are entitled to an indirect proportionate pecuniary interest in the Issuer's securities issued as compensation for Julian C. Baker and Dr. Cheong's service on the Board.

Stakeholder Impact

• Shareholders: The significant insider buying by a major institutional investor and directors could instill greater confidence and potentially lead to increased investor interest and share price appreciation.
• Employees: No direct impact mentioned, but a stronger stock performance could indirectly benefit employees through stock-based compensation or overall company stability.
• Customers/Suppliers/Creditors: No direct impact mentioned as the filing pertains to stock ownership, not operational changes.

Key Dates

Recommendation

The substantial insider buying by Baker Bros. Advisors, a highly respected and specialized biotech investor, and entities affiliated with Madrigal's directors, signals strong conviction in the company's future prospects. Such significant accumulation of shares at increasing prices by informed insiders is a powerful bullish indicator, suggesting that the stock is undervalued or poised for significant growth. This aligns the interests of major shareholders and management, making it a compelling investment opportunity.

Keywords

Madrigal Pharmaceuticals, MDGL, Baker Bros. Advisors, Insider Buying, SEC Form 4, Biotechnology, Pharmaceuticals, Institutional Investment, Stock Purchase, Beneficial Ownership